ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Neurology · J Headache Pain · 2026-06-13

In 608 adults with chronic migraine and medication-overuse headache given brief education, gains with eptinezumab over 12 weeks were sustained to 24 weeks in an open-label extension; placebo switchers improved similarly. TEAEs 30% vs 34%; no new safety signals.

RCTn = 608
Schytz et al. Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results of the randomized RESOLUTION trial
Neurology · Cephalalgia · 2026-05-16

Secondary analysis of a phase 4 RCT in adults with chronic migraine and medication-overuse headache (602 analysed): eptinezumab plus brief education improved patient-reported headache impact, disability and quality of life vs placebo from week 4 to 12.

Secondary analysisn = 608
Tepper et al. Benefits of eptinezumab on patient-reported disease burden and health-related quality of life in adults with chronic migraine and medication-overuse headache: Results from the placebo-controlled RESOLUTION trial
Neurology · Eur J Neurol · 2025-12-01

Post hoc analysis of the DELIVER trial (890 adults with migraine after 2-4 failed preventives): among those first given eptinezumab, 23% had <4 monthly headache days in weeks 1-12 and 47% in weeks 61-72; 71% who fell below 8 days early stayed there.

Secondary analysisn = 890 adults
Tassorelli et al. Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2-4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.